BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Oncology·MeSH: Recurrence
2 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| mekinist | Novartis AG (NVS) |
Unknown(1)
| Drug | Company |
|---|---|
| tafinlar/mekinist | Novartis AG (NVS) |
Compare drugs
Frequently asked questions
How many drugs are in development for BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor?
BioSniper tracks 2 drugs in development for BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor across 1 company.
How many clinical trials target BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor?
There are 1 clinical trial targeting BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor tracked by BioSniper.
Deep-dive into BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis